Peptic ulcer disease

The Lancet

Volumn 390, Issue 10094, 2017, Pages 613-624

  Lanas, Angel ^a   Chan, Francis K L ^b  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; BISMUTH CITRATE; CLARITHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; RIFABUTIN; TETRACYCLINE; ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; CLINICAL FEATURE; HELICOBACTER INFECTION; HUMAN; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PEPTIC ULCER; PEPTIC ULCER BLEEDING; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT PLANNING; ALGORITHM; COMBINATION DRUG THERAPY; COMPLICATION; GASTROINTESTINAL HEMORRHAGE; HELICOBACTER PYLORI;

ALGORITHMS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG THERAPY, COMBINATION; GASTROINTESTINAL HEMORRHAGE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER;

EID: 85013836543     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)32404-7     Document Type: Review

References (126)

1. Del Valle, J, Peptic ulcer disease and related disorders. Kasper, DL, Fauci, AS, Hauser, SL, Longo, DL, Jameson, JL, Loscalzo, J, (eds.) Harrison's Principles of Internal Medicine, 19th edn., 2015, McGraw Hill Education, New York, NY, 1911–1932.
2. Rosenstock, SJ, Jørgensen, T, Prevalence and incidence of peptic ulcer disease in a Danish County—a prospective cohort study. Gut 36 (1995), 819–824.
3. Kurata, JH, Nogawa, AN, Abbey, DE, Petersen, F, A prospective study of risk for peptic ulcer disease in seventh-day adventists. Gastroenterology 102 (1992), 902–909.
4. Sonnenberg, A, Review article: historic changes of Helicobacter pylori-associated diseases. Aliment Pharmacol Ther 38 (2013), 329–342.
5. Sonnenberg, A, Time trends of ulcer mortality in Europe. Gastroenterology 132 (2007), 2320–2327.
6. Sonnenberg, A, Time trends of ulcer mortality in non-European countries. Am J Gastroenterol 102 (2007), 1101–1107.
7. Leow, AH, Lim, YY, Liew, WC, Goh, KL, Time trends in upper gastrointestinal diseases and Helicobacter pylori infection in a multiracial Asian population — a 20-year experience over three time periods. Aliment Pharmacol Ther 43 (2016), 831–837.
8. Lanas, A, García-Rodríguez, LA, Polo-Tomás, M, et al. The changing face of hospitalisation due to gastrointestinal bleeding and perforation. Aliment Pharmacol Ther 33 (2011), 585–591.
9. Malmi, H, Kautiainen, H, Virta, LJ, Färkkilä, N, Koskenpato, J, Färkkilä, MA, Incidence and complications of peptic ulcer disease requiring hospitalisation have markedly decreased in Finland. Aliment Pharmacol Ther 39 (2014), 496–506.
10. Lanas, A, We are using too many PPIs, and we need to stop: a European perspective. Am J Gastroenterol 111 (2016), 1085–1086.
11. Zhang, BB, Li, Y, Liu, XQ, Wang, PJ, Yang, B, Bian, DL, Association between vacA genotypes and the risk of duodenal ulcer: a meta-analysis. Mol Biol Rep 41 (2014), 7241–7254.
12. Sugimoto, M, Yamaoka, Y, The association of vacA genotype and Helicobacter pylori-related disease in Latin American and African populations. Clin Microbiol Infect 15 (2009), 835–842.
13. Huang, JQ, Sridhar, S, Hunt, RH, Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 359 (2002), 14–22.
14. Datta, D, Roychoidhury, S, To be or not to be: the host genetic factor and beyond Helicobacter pylori mediated gastro-duodenal diseases. World J Gastroenterol 21 (2015), 2883–2895.
15. Shiotani, A, Graham, DY, Pathogenesis and therapy of gastric and duodenal ulcer disease. Med Clin North Am 86 (2002), 1447–1466.
16. Yamaoka, Y, Graham, DY, Helicobacter pylori virulence and cancer pathogenesis. Future Oncol 10 (2014), 1487–1500.
17. Wang, F, Meng, W, Wang, B, Qiao, L, Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett 345 (2014), 196–220.
18. Chen, MY, He, CY, Meng, X, Yuan, Y, Association of Helicobacter pylori babA2 with peptic ulcer disease and gastric cancer. World J Gastroenterol 19 (2013), 4242–4251.
19. Guo, T, Qian, JM, Zhao, YQ, Li, XB, Zhang, JZ, Effects of IL-1β on the proliferation and apoptosis of gastric epithelial cells and acid secretion from isolated rabbit parietal cells. Mol Med Rep 7 (2013), 299–305.
20. Furuta, T, El-Omar, EM, Xiao, F, Shirai, N, Takashima, M, Sugimura, H, Interleukin 1β polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. Gastroenterology 123 (2002), 92–105.
21. El-Omar, EM, Carrington, M, Chow, WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404 (2000), 398–402.
22. Chakravorty, M, Ghosh, A, Choudhury, A, Santra, A, Hembrum, J, Roychoudhury, S, Interaction between IL1B gene promoter polymorphisms in determining susceptibility to Helicobacter pylori associated duodenal ulcer. Hum Mutat 27 (2006), 411–419.
23. García-González, MA, Lanas, A, Savelkoul, PH, et al. Association of interleukin 1 gene family polymorphisms with duodenal ulcer disease. Clin Exp Immunol 134 (2003), 525–531.
24. Robert, A, Olafsson, AS, Lancaster, C, Zhang, WR, Interleukin-1 is cytoprotective, antisecretory, stimulates PGE2 synthesis by the stomach, and retards gastric emptying. Life Sci 48 (1991), 123–134.
25. Zhang, BB, Liu, XZ, Sun, J, Yin, YW, Sun, QQ, Association between TNF α gene polymorphisms and the risk of duodenal ulcer: a meta-analysis. PLoS One, 8, 2013, e57167.
26. Trejo-de la, OA, Torres, J, Sánchez-Zauco, N, et al. Polymorphisms in TLR9 but not in TLR5 increase the risk for duodenal ulcer and alter cytokine expression in the gastric mucosa. Innate Immun 21 (2015), 706–713.
27. Lanas, A, García-González, MA, Santolaria, S, et al. TNF and LTA gene polymorphisms reveal different risk in gastric and duodenal ulcer patients. Genes Immun 2 (2001), 415–421.
28. Mayerle, J, den Hoed, CM, Schurmann, C, et al. Identification of genetic loci associated with Helicobacter pylori serologic status. JAMA 309 (2013), 1912–1920.
29. Lanas, A, García-Rodríguez, LA, Arroyo, MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 55 (2006), 1731–1738.
30. Lanas, Á, Carrera-Lasfuentes, P, Arguedas, Y, et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol 13 (2015), 906–912.
31. Crooks, CJ, West, J, Card, TR, Comorbidities affect risk of nonvariceal upper gastrointestinal bleeding. Gastroenterology 144 (2013), 1384–1393.
32. Chan, FK, Goto, S, Wu, MS, et al. Burden of nonsteroidal anti-inflammatory and antiplatelet drug use in Asia: a multidisciplinary working party report. Clin Gastroenterol Hepatol 10 (2012), 753–760.
33. Masclee, GM, Valkhoff, VE, Coloma, PM, et al. Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology 147 (2014), 784–792.
34. González-Pérez, A, Sáez, ME, Johansson, S, Nagy, P, García Rodríguez, LA, Risk factors associated with uncomplicated peptic ulcer and changes in medication use after diagnosis. PLoS One, 9, 2014, e101768.
35. Tanikawa, C, Urabe, Y, Matsuo, K, et al. A genome-wide association study identifies two susceptibility loci for duodenal ulcer in the Japanese population. Nat Genet 44 (2012), 430–434.
36. García-González, MA, Bujanda, L, Quintero, E, et al. Association of PSCA rs2294008 gene variants with poor prognosis and increased susceptibility to gastric cancer and decreased risk of duodenal ulcer disease. Int J Cancer 137 (2015), 1362–1373.
37. Shiotani, A, Murao, T, Fujita, Y, et al. Single nucleotide polymorphism markers for low-dose aspirin-associated peptic ulcer and ulcer bleeding. J Gastroenterol Hepatol, 29(suppl 4), 2014 47–52.
38. Wang, PY, Chen, HP, Chen, A, et al. Impact of blood type, functional polymorphism (T-1676C) of the COX-1 gene promoter and clinical factors on the development of peptic ulcer during cardiovascular prophylaxis with low-dose aspirin. Biomed Res Int, 2014, 2014, 616018.
39. Shiotani, A, Fujita, Y, Nishio, K, Low-dose aspirin-associated upper and mid gastrointestinal tract damage and gene polymorphism. Curr Pharm Des 21 (2015), 5066–5072.
40. Malfertheiner, P, Megraud, F, O'Morain, CA, et al. Management of Helicobacter pylori infection—the Maastricht IV/Florence Consensus Report. Gut 61 (2012), 646–664.
41. Sostres, C, Carrera-Lasfuentes, P, Benito, R, et al. Peptic ulcer bleeding risk. The role of Helicobacter pylori infection in NSAID/low-dose aspirin users. Am J Gastroenterol 110 (2015), 684–689.
42. Gisbert, JP, Calvet, X, Review article: Helicobacter pylori-negative duodenal ulcer disease. Aliment Pharmacol Ther 30 (2009), 791–815.
43. Charpignon, C, Lesgourgues, B, Pariente, A, et al. Peptic ulcer disease: one in five is related to neither Helicobacter pylori nor aspirin/NSAID intake. Aliment Pharmacol Ther 38 (2013), 946–954.
44. Yamanaka, K, Miyatani, H, Yoshida, Y, et al. Hemorrhagic gastric and duodenal ulcers after the Great East Japan earthquake disaster. World J Gastroenterol 19 (2013), 7426–7432.
45. Kanno, T, Iijima, K, Koike, T, et al. Accommodation in a refugee shelter as a risk factor for peptic ulcer bleeding after the Great East Japan Earthquake: a case-control study of 329 patients. J Gastroenterol 50 (2015), 31–40.
46. Levenstein, S, Rosenstock, S, Jacobsen, RK, Jorgensen, T, Psychological stress increases risk for peptic ulcer, regardless of Helicobacter pylori infection or use of nonsteroidal anti-inflammatory drugs. Clin Gastroenterol Hepatol 13 (2015), 498–506.
47. Kiss, S, Zsikla, V, Frank, A, Willi, N, Cathomas, G, Helicobacter-negative gastritis: polymerase chain reaction for Helicobacter DNA is a valuable tool to elucidate the diagnosis. Aliment Pharmacol Ther 43 (2016), 924–932.
48. Meyer-Rosberg, K, Scott, DR, Rex, D, Melchers, K, Sachs, G, The effect of environmental pH on the proton motive force of Helicobacter pylori. Gastroenterology 111 (1996), 886–900.
49. Beales, IL, Calam, J, Inhibition of carbachol stimulated acid secretion by interleukin 1β in rabbit parietal cells requires protein kinase C. Gut 48 (2001), 782–789.
50. Zaki, M, Coudron, PE, McCuen, RW, Harrington, L, Chu, S, Schubert, ML, H. pylori acutely inhibits gastric secretion by activating CGRP sensory neurons coupled to stimulation of somatostatin and inhibition of histamine secretion. Am J Physiol Gastrointest Liver Physiol 304 (2013), G715–G722.
51. El-Omar, EM, Oien, K, El-Nujumi, A, et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 113 (1997), 15–24.
52. Moss, SF, Legon, S, Bishop, AE, Polak, JM, Calam, J, Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancet 340 (1992), 930–932.
53. Silverstein, FE, Graham, GY, Senior, JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatoy drugs. Ann Int Med 123 (1995), 241–249.
54. Bhala, N, Emberson, J, Merhi, A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382 (2013), 769–779.
55. Bjarnason, I, Scarpignato, C, Takeuchi, K, Rainsford, KD, Determinants of the short-term gastric damage caused by NSAIDs in man. Aliment Pharmacol Ther 26 (2007), 95–106.
56. Ligumski, M, Golanska, EM, Hansen, DG, Kauffman, GL, Aspirin can inhibit gastric mucosal cyclo-oxigenase without causing lesions in the rat. Gastroenterology 84 (1983), 756–761.
57. Wallace, JL, Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 112 (1997), 1000–1016.
58. Lanas, A, Panés, J, Piqué, JM, Clinical implications of COX-1 and/or COX-2 inhibition for the distal gastrointestinal tract. Curr Pharm Des 9 (2003), 2253–2266.
59. Sigthorsson, G, Tibble, J, Hayllar, J, et al. Intestinal permeability and inflammation in patients on NSAIDs. Gut 43 (1998), 506–551.
60. Cryer, B, Feldman, M, Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 117 (1999), 17–25.
61. Sostres, C, Lanas, A, Gastrointestinal effects of aspirin. Nat Rev Gastroenterol Hepatol 8 (2011), 385–394.
62. Perini, RF, Ma, L, Wallace, JL, Mucosal repair and COX-2 inhibition. Curr Pharm Des 9 (2003), 2207–2211.
63. McColl, KE, Helicobacter pylori-negative nonsteroidal anti-inflammatory drug-negative ulcer. Gastroenterol Clin North Am 38 (2009), 353–361.
64. Singh, G, Triadafilopoulos, G, Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl 56 (1999), 18–24.
65. Agréus, L, Talley, NJ, Jones, M, Value of the “Test & Treat” strategy for uninvestigated dyspepsia at low prevalence rates of Helicobacter pylori in the population. Helicobacter 23 (2016), 186–191.
66. Fock, KM, Katelaris, P, Sugano, K, et al. Second Asia-Pacific consensus guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 24 (2009), 1587–1600.
67. Fallone, CA, Chiba, N, van Zanten, SV, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology 151 (2016), 51–69.
68. Malfertheiner, P, Megraud, F, O'Morain, CA, et al. Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. Gut 66 (2017), 6–30.
69. Graham, DY, Laine, L, The Toronto Helicobacter pylori consensus in context. Gastroenterology 151 (2016), 9–12c.
70. Dore, MP, Lu, H, Graham, DY, Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut 65 (2016), 870–878.
71. Molina-Infante, J, Romano, M, Fernandez-Bermejo, M, et al. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology 145 (2013), 121–128.
72. Yuan, Y, Ford, AC, Khan, KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev, 12, 2013 CD008337.
73. Villoria, A, Garcia, P, Calvet, X, Gisbert, JP, Vergara, M, Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 28 (2008), 868–877.
74. Sun, Q, Liang, X, Zheng, Q, et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter 15 (2010), 233–238.
75. Gisbert, JP, Calvet, X, Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther 34 (2011), 604–617.
76. Gatta, L, Vakil, N, Vaira, D, Scarpignato, C, Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ, 347, 2013, f4587.
77. Nyssen, OP, McNicholl, AG, Megraud, F, et al. Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. Cochrane Database Syst Rev, 6, 2016 CD009034.
78. Hsu, PI, Lin, PC, Graham, DY, Hybrid therapy for Helicobacter pylori infection: a systemic review and meta-analysis. World J Gastroenterol 21 (2015), 12954–12962.
79. Hsu, PI, Kao, SS, Wu, DC, et al. A randomized controlled study comparing reverse hybrid therapy and standard triple therapy for Helicobacter pylori infection. Medicine, 94, 2015, e2104.
80. Murakami, K, Sakurai, Y, Shiino, M, Funao, N, Nishimura, A, Asaka, M, Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut 65 (2016), 1439–1446.
81. Chen, PY, Wu, MS, Chen, CY, et al. Systematic review with meta-analysis: the efficacy of levofloxacin triple therapy as the first- or second-line treatments of Helicobacter pylori infection. Aliment Pharmacol Ther 44 (2016), 427–437.
82. Trespalacios-Rangél, AA, Otero, W, Arévalo-Galvis, A, Poutou-Piñales, RA, Rimbara, E, Graham, DY, Surveillance of levofloxacin resistance in Helicobacter pylori isolates in Bogotá-Colombia (2009–2014). PLoS One, 11, 2016, e0160007.
83. Chuah, SK, Liang, CM, Lee, CH, et al. A randomized control trial comparing 2 levofloxacin-containing second-line therapies for Helicobacter pylori eradication. Medicine, 95, 2016, e3586.
84. Gisbert, JP, Romano, M, Gravina, AG, et al. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther 41 (2015), 768–775.
85. Gisbert, JP, Calvet, X, Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 35 (2012), 209–221.
86. Graham, DY, Lee, YC, Wu, MS, Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 12 (2014), 177–186.
87. Zeng, M, Mao, XH, Li, JX, et al. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 386 (2015), 1457–1464.
88. Taha, AS, McCloskey, C, Prasad, R, Bezlyak, V, Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 374 (2009), 119–125.
89. Ng, FH, Wong, SY, Lam, KF, et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology 138 (2010), 82–88.
90. Chan, FK, Kyaw, M, Tanigawa, T, et al. Similar efficacy of proton-pump inhibitors vs H2-receptor antagonists in reducing risk of upper gastrointestinal bleeding or ulcers in high-risk users of low-dose aspirin. Gastroenterology, 152, 2017, 105 10.e1.
91. Chan, FK, Ching, JY, Suen, BY, Tse, YK, Wu, JC, Sung, JJ, Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology 144 (2013), 528–535.
92. Scarpignato, C, Lanas, A, Blandizzi, C, Lems, WF, Hermann, M, Hunt, RH, for the International NSAID Consensus Group. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis—an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med, 13, 2015, 55.
93. Scheiman, JM, Fendrick, AM, Summing the risk of NSAID therapy. Lancet 369 (2007), 1580–1581.
94. Chan, FK, Primer: managing NSAID-induced ulcer complications—balancing gastrointestinal and cardiovascular risks. Nat Clin Pract Gastroenterol Hepatol 3 (2006), 563–573.
95. Yuan, JQ, Tsoi, KK, Yang, M, et al. Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity. Aliment Pharmacol Ther 43 (2016), 1262–1275.
96. Rostom, A, Muir, K, Dube, C, Lanas, A, Jolicoeur, E, Tugwell, P, Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. Drug Health Patient Saf 1 (2009), 47–71.
97. Regula, J, Butruk, E, Dekkers, CP, et al. Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole. Am J Gastroenterol 101 (2006), 1747–1755.
98. Yuan, JQ, Yang, M, Threapleton, DE, et al. Systematic review with meta-analysis: the gastrointestinal benefits of COX-2 selective inhibitors with concomitant use of low-dose aspirin. Aliment Pharmacol Ther 44 (2016), 785–795.
99. Chan, FK, Lanas, A, Scheiman, J, Berger, MF, Nguyen, H, Goldstein, JL, Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 376 (2010), 173–179.
100. Cryer, B, Li, C, Simon, LS, Singh, G, Stillman, MJ, Berger, MF, GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial. Am J Gastroenterol 108 (2013), 392–400.
101. Wallace, JL, Syer, S, Denou, E, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 141 (2011), 1314–1322.
102. Lanas, AI, Remacha, B, Esteva, F, Sáinz, R, Risk factors associated with refractory peptic ulcers. Gastroenterology 109 (1995), 1124–1133.
103. Hung, LC, Ching, JY, Sung, JJ, et al. Long-term outcome of Helicobacter pylori-negative idiopathic bleeding ulcers: a prospective cohort study. Gastroenterology 128 (2005), 1845–1850.
104. Wong, GL, Wong, VW, Chan, Y, et al. High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers. Gastroenterology 137 (2009), 525–531.
105. Wong, GL, Au, KW, Lo, AO, et al. Gastroprotective therapy does not improve outcomes of patients with Helicobacter pylori-negative idiopathic bleeding ulcers. Clin Gastroenterol Hepatol 10 (2012), 1124–1129.
106. Villanueva, C, Colomo, A, Bosch, A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 368 (2013), 11–21.
107. Stanley, AJ, Dalton, HR, Blatchford, O, et al. Multicenter comparison of the Glasgow Blatchford and Rockall Scores in the prediction of clinical end-points after upper gastrointestinal hemorrhage. Aliment Pharmacol Ther 34 (2011), 470–475.
108. Baker, DE, Peptic ulcer bleeding following therapeutic endoscopy: a new indication for intravenous esomeprazole. Rev Gastroenterol Disord 9 (2009), E111–E118.
109. Sreedharan, A, Martin, J, Leontiadis, GI, et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev, 7, 2010 CD005415.
110. Lau, JY, Barkun, A, Fan, DM, Kuipers, EJ, Yang, YS, Chan, FK, Challenges in the management of acute peptic ulcer bleeding. Lancet 381 (2013), 2033–2043.
111. Barkun, A, Bardou, M, Martel, M, Gralnek, IM, Sung, JY, Prokinetics in acute upper GI bleeding: a meta-analysis. Gastrointest Endosc 72 (2010), 1138–1145.
112. Cook, DJ, Guyatt, GH, Salena, BJ, Laine, LA, Endoscopic therapy for acute nonvariceal upper gastrointestinal hemorrhage: a meta-analysis. Gastroenterology 102 (1992), 139–148.
113. Sung, JJ, Tsoi, KK, Lai, LH, Wu, JC, Lau, JY, Endoscopic clipping versus injection and thermo-coagulation in the treatment of non-variceal upper gastrointestinal bleeding: a meta-analysis. Gut 56 (2007), 1364–1373.
114. Marmo, R, Rotondano, G, Bianco, MA, Piscopo, R, Prisco, A, Cipolletta, L, Outcome of endoscopic treatment for peptic ulcer bleeding: is a second look necessary? A meta-analysis. Gastrointest Endosc 57 (2003), 62–67.
115. Wang, CH, Ma, MH, Chou, HC, et al. High-dose vs. non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: a systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 170 (2010), 751–758.
116. Sachar, H, Vaidya, K, Laine, L, Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis. JAMA Intern Med 174 (2014), 1755–1762.
117. Hunfeld, N, Touw, D, Mathot, R, Mulder, P, Van Schaik, R, Kuipers, E, A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Aliment Pharmacol Ther 31 (2010), 150–159.
118. Lau, JY, Sung, JJ, Lam, YH, et al. Endoscopic re-treatment compared with surgery in patients with recurrent bleeding after initial endoscopic control of bleeding ulcers. N Engl J Med 340 (1999), 751–756.
119. Sung, JJ, Lau, JY, Ching, JY, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 152 (2010), 1–9.
120. Airoldi, F, Colombo, A, Morici, N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 116 (2007), 745–754.
121. Eisenstein, EL, Anstrom, KJ, Kong, DF, et al. Clopidogrel use and long-term clinical outcomes after drug eluting stent implantation. JAMA 297 (2007), 159–168.
122. Ruff, CT, Giugliano, RP, Braunwald, E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383 (2014), 955–962.
123. Witt, DM, Delate, T, Garcia, DA, et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med 17 (2012), 1–8.
124. Gralnek, IM, Dumonceau, JM, Kuipers, EJ, et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 47 (2015), a1–46.
125. Dumbleton, JS, Avery, AJ, Coupland, C, et al. The Helicobacter Eradication Aspirin Trial (HEAT): a large simple randomised controlled trial using novel methodology in primary care. EBioMedicine 2 (2015), 1200–1204.
126. Cremades, N, Velázquez-Campoy, A, Martínez-Júlvez, M, et al. Discovery of specific flavodoxin inhibitors as potential therapeutic agents against Helicobacter pylori infection. ACS Chem Biol 4 (2009), 928–938.